Processa Pharmaceuticals, Inc.
PCSAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 19, 2022 | Maxim Group | $9.00(-89%) | $79.61 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 13, 2024 |
| Benchmark | maintain | Speculative Buy | Mar 6, 2024 |
| Maxim Group | downgrade | Buy →Hold | Nov 17, 2023 |
| Benchmark | maintain | Speculative Buy | Apr 3, 2023 |
| Oppenheimer | maintain | Outperform | Apr 2, 2023 |
| Maxim Group | maintain | Buy | Jan 11, 2023 |
| Maxim Group | maintain | Buy | Apr 19, 2022 |
| Oppenheimer | maintain | Outperform | Aug 3, 2021 |
| Oppenheimer | maintain | Outperform | Aug 2, 2021 |
| Craig-Hallum | maintain | Buy | Oct 28, 2020 |
Earnings History
Next report: Mar 3, 2027 · EPS est. $-0.75| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-1.19 | $-1.00 | — | — |
| May 7, 2026 | $-1.29 | $-1.00 | — | — |
| Mar 19, 2026 | $-18.50 | $-1.50 | — | — |
| Nov 6, 2025 | $-1.75 | $-2.00 | — | — |
| Aug 7, 2025 | $-6.25 | $-5.75 | — | — |
| May 8, 2025 | $-7.50 | $-19.25 | — | — |
| Mar 20, 2025 | $-18.50 | $-0.76 | — | — |
| Oct 30, 2024 | $-1.03 | $-1.00 | — | — |
News
VERO BEACH, FL, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today announced its participation in two upcoming conferences. Sheila Gujrathi, M.D.
VERO BEACH, FL, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today announced key leadership appointments to support the Company's next phase of growth: Gregory J. Flesher, Chief Operating Officer Craig Coburn, Ph.D.
VERO BEACH, FL, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced continued execution following its acquisition of Vidya Therapeutics (“Vidya”). Progress includes U.S. Food and Drug Administration (FDA) clearance of the investigational new drug (IND) application for a Phase 2 study…
VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conferences.